Senti Biosciences Stock Today
| SNTI Stock | USD 3.62 0.03 0.82% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Senti Biosciences is trading at 3.62 as of the 20th of March 2025. This is a 0.82 percent decrease since the beginning of the trading day. The stock's open price was 3.65. Senti Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of June 2022 | Category Healthcare | Classification Health Care |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. The company was incorporated in 2016 and is headquartered in South San Francisco, California. The company has 4.59 M outstanding shares of which 68.62 K shares are at this time shorted by private and institutional investors with about 3.27 trading days to cover. More on Senti Biosciences
Moving together with Senti Stock
| 0.62 | A | Agilent Technologies | PairCorr |
| 0.66 | ME | 23Andme Holding | PairCorr |
| 0.83 | VANI | Vivani Medical Earnings Call This Week | PairCorr |
Moving against Senti Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Senti Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Head President | Kanya MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSenti Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Senti Biosciences' financial leverage. It provides some insight into what part of Senti Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Senti Biosciences (SNTI) is traded on NASDAQ Exchange in USA. It is located in 2 Corporate Drive, South San Francisco, CA, United States, 94080 and employs 48 people. Senti Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.89 M. Senti Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.59 M outstanding shares of which 68.62 K shares are at this time shorted by private and institutional investors with about 3.27 trading days to cover.
Senti Biosciences currently holds about 140.78 M in cash with (52.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24.
Check Senti Biosciences Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Senti Biosciences is $45.89 Million. Senti Biosciences maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Senti Ownership Details
Senti Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 120 | |
| Ark Investment Management Llc | 2024-12-31 | 28.0 | |
| Citigroup Inc | 2024-12-31 | 1.0 | |
| Harbour Investments, Inc. | 2024-12-31 | 0.0 | |
| Barclays Plc | 2024-12-31 | 0.0 | |
| Nea Management Company, Llc | 2024-12-31 | 442.6 K | |
| Vanguard Group Inc | 2024-12-31 | 97.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 51.6 K | |
| Geode Capital Management, Llc | 2024-12-31 | 27.5 K | |
| Ubs Group Ag | 2024-12-31 | 19 K | |
| Virtu Financial Llc | 2024-12-31 | 13.4 K |
Senti Biosciences Historical Income Statement
Senti Stock Against Markets
Senti Biosciences Corporate Management
| Faraz Siddiqui | Senior Operations | Profile | |
| Thomas Chung | Vice Development | Profile | |
| Susan Kahlert | Controller | Profile | |
| Wilson Wong | Scientific Board | Profile | |
| Philip Lee | CoFounder CTO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.